NDAINHALATIONSOLUTION
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
KITABIS PAK (tobramycin) by Viatris (2) is [see microbiology ()]. Approved for cystic fibrosis, conjunctivitis, pseudomonas aeruginosa infection and 9 more indications. First approved in 2014.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KITABIS PAK is an inhaled tobramycin solution approved for cystic fibrosis and Pseudomonas aeruginosa respiratory infections. It is an aminoglycoside antibacterial that inhibits bacterial protein synthesis. The inhalation route delivers high local lung concentrations for treating chronic pulmonary infections in CF patients.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), indicating stable commercial operations and established field teams.
Mechanism of Action
[see Microbiology ()].
Pharmacologic Class:
Aminoglycoside Antibacterial
Indications (12)
Worked on KITABIS PAK at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.